Advice

following an independent review panel:

abiraterone acetate (Zytiga®) is accepted for use  within NHS Scotland.

Indication under review: abiraterone acetate is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

In a randomised, double-blind phase III study of adult men with chemotherapy-naive mCRPC, treatment with abiraterone acetate in combination with corticosteroid was associated with a statistically significant extended progression-free survival and overall survival when compared with placebo plus corticosteroid.
 
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of abiraterone acetate. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
 

Download detailed advice204KB (PDF)

Download

Medicine details

Medicine name:
abiraterone (Zytiga)
SMC ID:
873/13
Indication:
abiraterone acetate is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
IRP
Status
Accepted
Date advice published:
12 October 2015